Life Sciences Power Breakfast 2020: Lilly’s COVID-19 therapy
October 9, 2020Andrew Adams, VP of new therapeutic modalities for Eli Lilly and Co., charts the path of the pharmaceutical company’s new antibody therapy for COVID-19 from development to testing to the submission for emergency use with the FDA.
